Header cover image

Taiwanese (TAIEX) Clinical Research and Equipment Industry Analysis

UpdatedMar 23, 2024
DataAggregated Company Financials
Companies9
  • 7D0.2%
  • 3M-12.3%
  • 1Y-27.1%
  • YTDn/a

Last week, the Clinical Research and Equipment industry hasn't moved much but Locus Cell is up 11% in that time. As for the longer term, the industry has declined 27% in the last year. As for the next few years, earnings are expected to grow by 117% per annum.

Industry Valuation and Performance

Has the Taiwanese Clinical Research and Equipment Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sun, 24 Mar 2024NT$40.2bNT$2.1b-NT$606,177,000.0031.3x-66.4x19.4x
Tue, 20 Feb 2024NT$44.3bNT$2.1b-NT$610,218,000.0033.1x-72.5x21.3x
Thu, 18 Jan 2024NT$44.6bNT$2.1b-NT$610,218,000.0032.7x-73.1x21.5x
Sat, 16 Dec 2023NT$48.6bNT$2.1b-NT$610,218,000.0032.8x-79.7x23.4x
Mon, 13 Nov 2023NT$48.2bNT$2.2b-NT$497,769,000.0031.7x-96.9x21.7x
Wed, 11 Oct 2023NT$48.3bNT$2.2b-NT$497,769,000.0031.4x-97.1x21.7x
Fri, 08 Sep 2023NT$43.1bNT$2.2b-NT$497,769,000.0031.6x-86.6x19.4x
Sun, 06 Aug 2023NT$47.1bNT$2.4b-NT$281,587,000.0044.7x-167.4x19.3x
Tue, 04 Jul 2023NT$49.6bNT$2.5b-NT$274,767,000.0043.3x-180.4x20.2x
Thu, 01 Jun 2023NT$50.6bNT$2.5b-NT$262,467,000.0043.4x-192.9x20.4x
Sat, 29 Apr 2023NT$46.8bNT$2.7b-NT$29,017,000.0023.7x-1612.6x17.6x
Mon, 27 Mar 2023NT$49.4bNT$2.7b-NT$29,761,000.0024.7x-1661.2x18.6x
Wed, 22 Feb 2023NT$51.1bNT$2.7bNT$85.3m21.6x599.8x19.1x
Fri, 20 Jan 2023NT$45.3bNT$2.7bNT$85.3m19.1x531.4x16.9x
Sun, 18 Dec 2022NT$50.4bNT$2.7bNT$139.5m18.7x361.7x18.9x
Tue, 15 Nov 2022NT$47.6bNT$2.7bNT$139.5m18.9x341.5x17.8x
Thu, 13 Oct 2022NT$46.3bNT$3.0bNT$482.8m24x95.9x15.5x
Sat, 10 Sep 2022NT$50.3bNT$3.0bNT$482.8m27x104.2x16.8x
Mon, 08 Aug 2022NT$39.6bNT$3.1bNT$325.5m37.7x121.6x12.9x
Wed, 06 Jul 2022NT$37.9bNT$3.1bNT$325.1m36x116.5x12.3x
Fri, 03 Jun 2022NT$30.7bNT$3.1bNT$325.1m36.3x94.4x10x
Sun, 01 May 2022NT$34.5bNT$3.2bNT$164.4m28.1x209.7x10.8x
Tue, 29 Mar 2022NT$32.8bNT$3.0b-NT$134,053,000.0027.3x-244.5x10.9x
Thu, 24 Feb 2022NT$36.7bNT$3.0b-NT$120,147,000.0034.5x-305.4x12x
Sat, 22 Jan 2022NT$36.5bNT$3.0b-NT$120,147,000.0035x-303.8x12x
Mon, 20 Dec 2021NT$38.5bNT$3.0b-NT$120,147,000.0037.4x-320.8x12.6x
Wed, 17 Nov 2021NT$30.4bNT$3.0b-NT$120,147,000.0035.2x-253x10x
Fri, 15 Oct 2021NT$29.9bNT$2.3b-NT$631,150,000.0031.3x-47.3x12.8x
Sun, 12 Sep 2021NT$35.0bNT$2.3b-NT$631,150,000.0031.8x-55.4x15x
Tue, 10 Aug 2021NT$37.6bNT$2.3b-NT$631,150,000.0032.4x-59.5x16.1x
Mon, 03 May 2021NT$33.9bNT$2.2b-NT$810,177,000.0029.2x-41.8x15.6x
Price to Earnings Ratio

-34.4x


Total Market Cap: NT$27.9bTotal Earnings: -NT$810,177,000.00Total Revenue: NT$2.2bTotal Market Cap vs Earnings and Revenue0%0%0%
Taiwanese Clinical Research and Equipment Industry Price to Earnings3Y Average -89.9x202220232024
Current Industry PE
  • Investors are optimistic on the Taiwanese Life Sciences Tools and Services industry, and appear confident in long term growth rates.
  • The 3-year average PS ratio of 16.6x is lower than the industry's current PS ratio of 19.4x.
Past Earnings Growth
  • The earnings for companies in the Life Sciences Tools and Services industry have improved over the last three years.
  • Meanwhile revenues have remained mostly flat.
  • This means that companies overall are more efficiently conducting business since losses are shrinking while sales have been flat.

Industry Comparison

How does Taiwanese Clinical Research and Equipment compare with similar industries?

TW Market2.69%
Healthcare1.85%
Life Sciences0.19%
Clinical Research and Equipment0.19%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
6891 Locus CellNT$24.9510.9%
+NT$490.0m
-46.5%PB2.7x
6986 HeXun BiosciencesNT$54.002.7%
+NT$64.4m
n/an/a
4133 Abnova (Taiwan)NT$31.750.8%
+NT$15.1m
-14.9%PE44x
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.

Latest News

6662

NT$35.90

BioLASCO Taiwan

7D

-2.2%

1Y

13.4%

6891

NT$24.95

Locus Cell

7D

10.9%

1Y

-46.5%

6661

NT$22.50

Welgene BiotechLtd

7D

-1.5%

1Y

-6.6%

6589

NT$87.20

EirGenix

7D

-1.4%

1Y

-24.2%

4133

NT$31.75

Abnova (Taiwan)

7D

0.8%

1Y

-14.9%

6848

NT$15.75

RBC Bioscience

7D

-0.9%

1Y

-7.1%

7607

NT$35.00

DuoGenic StemCells

7D

-4.0%

1Y

n/a

6939

NT$41.35

TFBS Bioscience

7D

-3.5%

1Y

n/a

6986

NT$54.00

HeXun Biosciences

7D

2.7%

1Y

n/a